膜杰作
Star Staining
分子别名（Synonym）
RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
表达区间及表达系统（Source）
FITC-Labeled Human VEGF165, His Tag (VE5-HF248) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
Predicted N-terminus: His
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 21.1 kDa. The protein migrates as 27-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
偶联（Conjugate）
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
标记（Labeling）
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
蛋白标记度（Protein Ratio）
The FITC to protein molar ratio is 1.5-3.5.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>90% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
FITC-Labeled Human VEGF165, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
活性（Bioactivity）-ELISA
Immobilized Bevacizumab at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human VEGF165, His Tag (Cat. No. VE5-HF248) with a linear range of 39-156 ng/mL (QC tested).
Protocol
背景（Background）
VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
